Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of
BGB-3245 in participants with advanced or refractory tumors harboring specific v-RAF murine
sarcoma viral oncogene homolog B (B-RAF) genetic mutations.